Suzhou Huyun New Drug Research & Development

Suzhou Huyun New Drug Research & Development is a clinical-stage biotechnology company based in Suzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses primarily on high-prevalence chronic conditions, including cardiovascular diseases, metabolic disorders, and inflammatory conditions. Its lead candidate, HY-0003, is a novel P2Y12 receptor antagonist designed for anti-platelet therapy to prevent thrombotic events. Suzhou Huyun leverages its internal R&D capabilities to advance a pipeline of candidates targeting validated pathways such as SGLT2 and PCSK9. The company aims to provide high-quality, affordable innovative medicines for the global and domestic Chinese markets.